Exact Sciences Corporation raised revenue guidance for the full year 2023. For the period, the company expects revenue to be in the range of $2.476 billion - $2.486 billion, assuming: Screening revenue of $1.848 billion - $1.853 billion, precision Oncology revenue of $622 million - $627 million, and COVID-19 testing revenue of $6 million compared to previous revenue guidance of $2.441 billion - $2.466 billion, which assumed screening revenue of $1.820 billion - $1.835 billion, precision Oncology revenue of $615 million - $625 million, and COVID-19 testing revenue of $6 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
53.51 USD | -1.18% | -13.79% | -27.67% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-27.67% | 9.87B | |
+34.87% | 3.07B | |
-17.30% | 2.73B | |
-11.15% | 2.24B | |
-22.32% | 1.63B | |
+23.58% | 771M | |
-1.31% | 760M | |
-28.57% | 516M | |
+5.37% | 310M | |
+12.46% | 219M |
- Stock Market
- Equities
- EXAS Stock
- News Exact Sciences Corporation
- Exact Sciences Corporation Raises Revenue Guidance for the Full Year 2023